Meeting
2012 ASCO Annual Meeting
The role of fluorescence-guided surgical resection in the combined treatment of malignant glioma.
Authors
Carmine Maria Carapella
Neurosurgery, Cancer Institute Regina Elena, Roma, Italy
Carmine Maria Carapella , Piero Andrea Oppido , Antonello Vidiri , Fabio Cattani , Stefano Maria Telera , Alfredo Pompili , Andrea Pace
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 30, 2012 (suppl; abstr 2085)
DOI
10.1200/jco.2012.30.15_suppl.2085
Abstract #
2085
Poster Bd #
17H
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2022 ASCO Annual Meeting
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
First Author: Julia Katharina Schwarze
Poster
2021 ASCO Annual Meeting
LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.
First Author: Andrew E. Sloan
Poster
2020 ASCO Virtual Scientific Program
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.
First Author: Sylvia Christine Kurz